PDS Biotechnology Corporation - PDSB STOCK NEWS

PDS Biotechnology Corporation (Nasdaq: PDSB) has successfully closed its underwritten public offering of 6,900,000 shares of common stock at a price of $2.75 per share, yielding approximately $19.0 million in gross proceeds. The offering included 900,000 additional shares exercised by the underwriter. Several company insiders participated in the purchase. The shares were offered under a registration statement filed with the SEC. This initiative is aimed at enhancing the company's financial position as it advances its proprietary Versamune® T-cell activating technology for cancer therapies and vaccines.

PDS Biotechnology Corporation (PDSB) announced its Q2 2020 financial results, reporting a net loss of $2.9 million or $0.19 per share, an improvement from a net loss of $3.9 million in Q2 2019. R&D and G&A expenses decreased by 26% and 38%, respectively. The company initiated a Phase 2 trial for PDS0101 to treat HPV-associated cancers and launched new COVID-19 vaccine programs. A collaborative grant was received from NIAID for developing a universal influenza vaccine. PDSB's cash balance stood at approximately $16.9 million as of June 30, 2020.

PDS Biotechnology has announced a public offering of 6,000,000 shares of common stock at $2.75 each, aiming to raise approximately $16.5 million.

The offering, set to close on August 13, 2020, includes an option for underwriters to buy 900,000 additional shares.

Proceeds will fund working capital and general corporate purposes, enhancing its ability to develop cancer therapies and vaccines utilizing its Versamune^® technology.

PDS Biotechnology Corporation (PDSB) will announce its second-quarter financial results for the period ending June 30, 2020, on August 13, 2020, before market opening. Following the announcement, executives including Dr. Frank Bedu-Addo will host a conference call to discuss the results and provide a business update at 8:00 am ET. Interested parties can join via phone or through a live webcast on PDS Biotech’s investor relations page. The event will be archived for six months for further access.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced promising preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203). The data show that PDS0203 effectively induces both CD8 killer and CD4 helper T-cells, leading to a 30-45 fold increase in COVID-19 specific T-cells and a 20-25 fold increase in neutralizing antibodies within 14 days. The vaccine demonstrates potential for long-lasting immunity, with effects continuing beyond 30 days. The company also initiated preclinical development for a second candidate, Versamune-CoV-2FC (PDS0204), in partnership with Farmacore Biotechnology.

PDS Biotechnology Corporation (Nasdaq: PDSB) has entered a co-development agreement with Farmacore Biotechnology to accelerate the development of the Versamune^®-CoV-2FC vaccine designed to prevent COVID-19. The Brazilian Ministry of Science, Technology, Innovation and Communication will provide initial funding support. This partnership aims to advance the vaccine to Phase 1 clinical trials in Brazil and leverages the Versamune^® T-cell activating technology alongside a recombinant SARS-CoV-2 protein. Commercialization rights are retained by Farmacore in Latin America.

PDS Biotechnology Corporation (Nasdaq: PDSB) has announced the dosing of the first patient in a Phase 2 clinical trial for PDS0101, targeting advanced HPV-associated cancers. Conducted by the National Cancer Institute (NCI), the study evaluates a combination of PDS0101 with Bintrafusp alfa and NHS-IL12 in approximately 35 patients. Initial safety and objective responses will be assessed from the first eight patients. This trial aims to enhance the efficacy of PDS0101 through the Versamune^® platform, demonstrating its potential in improving outcomes for patients with advanced cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the publication of an abstract on preclinical studies of PDS0102 at the ASCO Virtual Scientific Program, indicating the Versamune® platform's efficacy in inducing strong killer T-cell responses across various tumors. The study shows that PDS0102, targeting prostate and breast cancers, can activate T-cells that specifically attack cancer cells expressing the TARP protein, associated with an anticipated 450,000 diagnoses this year. These findings demonstrate the potential versatility and effectiveness of the Versamune® technology in immuno-oncology.

PDS Biotechnology Corporation (PDSB) reported its financial results for Q1 2020, showing a net loss of approximately $4.0 million, or $0.39 per share, compared to a net income of $6.8 million in Q1 2019. Research and development expenses increased by 91% to $1.9 million while general and administrative expenses decreased by 47% to $2.1 million. The company initiated vaccine development for COVID-19 and influenza, and secured a U.S. patent for its Versamune® platform. As of March 31, 2020, PDSB held approximately $21.0 million in cash, including net proceeds from a public offering in February.